tiprankstipranks
Trending News
More News >
Noevir Holdings Co., Ltd. (JP:4928)
:4928
Japanese Market
Advertisement

Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4928

Noevir Holdings Co., Ltd.

(4928)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
¥5,082.00
▲(14.85% Upside)
Noevir Holdings scores well due to its strong financial performance and attractive valuation, with a high dividend yield. The technical analysis suggests some short-term weakness, but the long-term trend remains positive. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Noevir Holdings Co., Ltd. (4928) vs. iShares MSCI Japan ETF (EWJ)

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company DescriptionNoevir Holdings Co., Ltd. develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics segment develops, produces, and sells skincare products under various brands, including Noevir and Nameraka Honpo; and NOV hypoallergenic cosmetics, as well as provides contract manufacturing services for cosmetics and quasi drugs. Its Pharmaceutical & Health Food segment produces and sells Nanten Nodo Ame cough drops; functional drinks, such as the Min Min Da Ha; and over-the-counter pharmaceuticals comprising cold remedies, eye drops, and digestive aids, as well as nutritional supplements, and other products. The company's Other segment sells and leases apparels and aircrafts. The company also produces and sells toiletries; purchases and sells makeup products and vessels; and provides market research services. In addition, it provides air transportation, charter flights, ground handling, and hanger rental services; and aircraft flight training, as well as undertakes aviation-related operations. The company sells its products through drug stores, specialty goods and general merchandise stores, supermarkets, online stores, and convenience stores, as well as approximately 2,000 Noevir beauty studios and own retail stores. Noevir Holdings Co., Ltd. was founded in 1964 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyNoevir Holdings Co., Ltd. generates revenue primarily through the sale of its cosmetics and skincare products, which are distributed via direct sales channels, retail stores, and online platforms. The company's revenue model is supported by a strong network of sales representatives and partnerships with retail chains. Additionally, Noevir benefits from its presence in the health care and nutritional supplements markets, where it sells various products aimed at enhancing health and wellness. The company also engages in research and development to continually innovate its product offerings, thereby maintaining a competitive edge in the beauty and health industries.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary
Noevir Holdings demonstrates strong financial health with consistent profitability and a solid balance sheet. While revenue has recently declined, the company maintains efficient operations and low leverage. Cash flow metrics are stable, though there is potential for enhanced cash flow management.
Income Statement
75
Positive
Noevir Holdings shows strong profitability with a consistent gross profit margin around 67% and a stable net profit margin of approximately 12.5%. However, the recent TTM data indicates a slight revenue decline of 2.1%, contrasting with previous growth trends. EBIT and EBITDA margins remain healthy, reflecting efficient operations.
Balance Sheet
80
Positive
The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.016, indicating minimal leverage. Return on equity is strong at 16.1%, showcasing effective use of equity. The equity ratio is solid, reflecting a stable financial position.
Cash Flow
70
Positive
Operating cash flow to net income ratio is moderate at 0.62, and free cash flow to net income ratio is healthy at 0.74. Free cash flow growth is positive at 8.5% in the TTM period, although it has fluctuated in prior years. Cash flow management appears stable but with room for improvement.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue62.87B63.82B62.55B61.14B51.27B51.84B
Gross Profit42.40B43.16B42.56B42.09B33.03B33.08B
EBITDA11.77B12.44B12.24B11.57B10.05B9.76B
Net Income7.60B7.97B7.67B7.59B6.38B5.62B
Balance Sheet
Total Assets73.36B76.47B77.25B76.78B80.45B80.05B
Cash, Cash Equivalents and Short-Term Investments25.47B29.22B28.88B29.75B31.10B29.46B
Total Debt764.00M828.00M914.00M1.00B1.11B1.22B
Total Liabilities22.97B22.57B24.04B24.40B28.22B27.81B
Stockholders Equity49.82B53.48B52.79B52.05B51.93B51.98B
Cash Flow
Free Cash Flow5.51B8.11B6.57B5.23B8.63B5.67B
Operating Cash Flow7.40B9.12B7.62B5.84B9.06B7.31B
Investing Cash Flow-12.13B1.52B-3.54B-255.00M-416.00M-1.61B
Financing Cash Flow-7.87B-7.71B-7.49B-7.38B-7.18B-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price4425.00
Price Trends
50DMA
4428.63
Negative
100DMA
4266.18
Positive
200DMA
4235.32
Positive
Market Momentum
MACD
13.47
Positive
RSI
47.62
Neutral
STOCH
7.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Neutral. The current price of 4425 is below the 20-day moving average (MA) of 4446.14, below the 50-day MA of 4428.63, and above the 200-day MA of 4235.32, indicating a neutral trend. The MACD of 13.47 indicates Positive momentum. The RSI at 47.62 is Neutral, neither overbought nor oversold. The STOCH value of 7.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
¥150.63B19.815.10%-1.63%1.81%
69
Neutral
¥421.21B20.557.05%1.86%1.29%4.72%
68
Neutral
¥293.90B45.765.63%3.91%-0.89%-34.14%
61
Neutral
¥343.73B111.862.76%2.32%2.82%-79.45%
57
Neutral
¥398.85B33.454.72%1.92%-6.64%-13.78%
55
Neutral
¥1.02T-786.28-0.21%1.96%-3.60%-112.93%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4928
Noevir Holdings Co., Ltd.
4,425.00
-528.42
-10.67%
JP:4967
Kobayashi Pharmaceutical Co
5,378.00
-284.72
-5.03%
JP:4922
Kose
6,025.00
-2,967.18
-33.00%
JP:4912
Lion
1,557.50
0.25
0.02%
JP:4927
Pola Orbis Holdings
1,328.50
-174.99
-11.64%
JP:4911
Shiseido Company,Limited
2,547.00
-1,230.66
-32.58%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Decline in Nine-Month Financial Results
Aug 5, 2025

Noevir Holdings Co., Ltd. reported a decline in its financial performance for the first nine months of the fiscal year ending September 30, 2025, with net sales and operating income both experiencing decreases compared to the previous year. Despite the downturn, the company maintains its dividend forecast and anticipates slight growth in net sales and income for the full fiscal year, suggesting a cautious optimism in its future operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025